Nitrogen-containing bisphosphate drugs used in the treatment of osteoporosis reduce farnesyldiphosphate production and thus prelamin A farnesylation.
In osteoporosis treatment, nitrogen-containing bisphosphonates lower farnesyldiphosphate levels, which in turn prevents the farnesylation of prelamin A.